Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Cancer Res. 2017 Jul 6;77(18):4846–4857. doi: 10.1158/0008-5472.CAN-17-0282

Figure 7. Proposed model of stroma mediated activation of WNT/β-Catenin signaling in MDS.

Figure 7

Aberrant methylation and underexpression of WNT/β-Catenin antagonists FRZB and SFRP1 is seen in MDS stroma. Activation of β-Catenin leads to disease progression in vivo and a WNT/β-catenin activation signature correlates with advanced disease in human samples (A). 5-Azacytidine treated MDS stroma samples have higher FRZB levels and in vitro treatment can lead to increased erythroid differentiation (B). (LSC, Leukemia stem cells).